Effectiveness and safety of a disposable elastomeric continuous infusion pump for outpatient parenteral antimicrobial therapy (OPAT) in a UK setting
J Chemother. 2023 Nov 9:1-8. doi: 10.1080/1120009X.2023.2277507. Online ahead of print.ABSTRACTWe evaluated the effectiveness and safety of continuous antimicrobial infusion using a disposable elastomeric device in an outpatient parenteral antimicrobial therapy (OPAT) setting. We conducted a retrospective analysis of all patients who received either flucloxacillin (n = 131 episodes) or piperacillin/tazobactam (n = 301 episodes) as continuous infusion via elastomeric devices over 5 years (January 2018-December 2022) at a tertiary referral hospital in Derbyshire, UK. Overall, 81 adverse events were recorded in 77 (18%; 77/43...
Source: Journal of Chemotherapy - November 9, 2023 Category: Cancer & Oncology Authors: Oyewole Christopher Durojaiye Joby Cole Evangelos I Kritsotakis Source Type: research
Recent advances in caspase-3, breast cancer, and traditional Chinese medicine: a review
J Chemother. 2023 Nov 7:1-19. doi: 10.1080/1120009X.2023.2278014. Online ahead of print.ABSTRACTCaspases (cysteinyl aspartate-specific proteinases) are a group of structurally similar proteases in the cytoplasm that can be involved in cell differentiation, programmed death, proliferation, and inflammatory generation. Experts have found that caspase-3 can serve as a terminal splicing enzyme in apoptosis and participate in the mechanism by which cytotoxic drugs kill cancer cells. Breast cancer (BC) has become the most common cancer among women worldwide, posing a severe threat to their lives. Finding new therapeutic targets ...
Source: Journal of Chemotherapy - November 8, 2023 Category: Cancer & Oncology Authors: He Dou Ping Yang Yu Yu Qi Liu Yue Zhu Fu Cheng Li You Yu Wang Xing Yan Chen Min Xiao Source Type: research
Enhanced synergy of pacritinib with temsirolimus and sunitinib in preclinical renal cell carcinoma model by targeting JAK2/STAT pathway
J Chemother. 2023 Nov 2:1-11. doi: 10.1080/1120009X.2023.2274700. Online ahead of print.ABSTRACTPacritinib is an oral medication that inhibits several kinases including JAK2, FLT3, IRAK and STAT3. It has been recently approved to treat patients with thrombocytopenia and myelofibrosis. Studies are currently exploring the potential use of pacritinib in treating other types of cancer such as leukaemia, breast cancer and prostate cancer. Our study aimed to investigate the effects of pacritinib alone and its combination with standard of care in renal cell carcinoma (RCC). We showed that pacritinib dose-dependently decreased via...
Source: Journal of Chemotherapy - November 2, 2023 Category: Cancer & Oncology Authors: Fei Mao Liangkui Gao Liming Liu Yuanjia Tang Source Type: research
Benefit from Almonertinib after Osimertinib treat EGFR 19 exon deletion NSCLC induced Severe rash: a case report
J Chemother. 2023 Nov 1:1-9. doi: 10.1080/1120009X.2023.2276574. Online ahead of print.ABSTRACTOsimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has been recommended as a first-line treatment of EGFR-positive non-small cell lung cancer (NSCLC). Skin rash is one of the most common side effects of osimertinib, and can have an impact on patients' quality of life and follow-up. However, there are few reports on the safety and efficacy of switching therapy with osimertinib and the other three generations of TKIs. In this paper, we present a case of NSCLC with an EGFR exon 1...
Source: Journal of Chemotherapy - November 1, 2023 Category: Cancer & Oncology Authors: Qichen Zhang Peng Xie Xiaoming Hou Chengpeng Zhao Ling Duan Hui Qiao Source Type: research
Sorafenib tosylate-loaded nanosuspension: preparation, optimization, and < em > in vitro < /em > cytotoxicity study against human HepG2 carcinoma cells
This study aimed to optimize nanosuspension of sorafenib tosylate (an anticancer hydrophobic drug molecule) using a central composite design. Nanosuspension was prepared using a nanoprecipitation-ultrasonication approach. FTIR and DSC analyses demonstrated that the drug and excipients were physicochemically compatible. X-ray powder diffraction analysis confirmed amorphous form of the payload in the formulation. The optimized formulation (batch NSS6) had a zeta potential of -18.1 mV, a polydispersity of 0.302, and a particle size of 97.11 nm. SEM analysis confirmed formation of rod-shaped particles. After 24 h, about 64.45%...
Source: Journal of Chemotherapy - October 26, 2023 Category: Cancer & Oncology Authors: Harpreet Kaur Khanuja Rajendra Awasthi Harish Dureja Source Type: research
Adjuvant chemotherapy for elderly patients with colorectal cancer: a single-centre observational study in Japan
We examined 1138 Japanese patients who were operated for high-risk stage II or stage III CRC between July 2010 and June 2021 at our hospital. Patients were divided according to an age of 70 years. The efficacy of adjuvant therapy was analyzed in association with age and adjuvant chemotherapeutic regimens. A total of 507 patients (45%) were ≥70 years old. They were less likely to receive adjuvant chemotherapy (p < 0.001) or palliative chemotherapy after recurrence (p < 0.001) than patients aged <70 years. Cancer-specific survival (CSS) in stage III CRC patients was longer in the <70 years group than in the ≥...
Source: Journal of Chemotherapy - October 26, 2023 Category: Cancer & Oncology Authors: Kazuaki Okamoto Hiroaki Nozawa Shigenobu Emoto Koji Murono Kazuhito Sasaki Soichiro Ishihara Source Type: research
Sorafenib tosylate-loaded nanosuspension: preparation, optimization, and < em > in vitro < /em > cytotoxicity study against human HepG2 carcinoma cells
This study aimed to optimize nanosuspension of sorafenib tosylate (an anticancer hydrophobic drug molecule) using a central composite design. Nanosuspension was prepared using a nanoprecipitation-ultrasonication approach. FTIR and DSC analyses demonstrated that the drug and excipients were physicochemically compatible. X-ray powder diffraction analysis confirmed amorphous form of the payload in the formulation. The optimized formulation (batch NSS6) had a zeta potential of -18.1 mV, a polydispersity of 0.302, and a particle size of 97.11 nm. SEM analysis confirmed formation of rod-shaped particles. After 24 h, about 64.45%...
Source: Journal of Chemotherapy - October 26, 2023 Category: Cancer & Oncology Authors: Harpreet Kaur Khanuja Rajendra Awasthi Harish Dureja Source Type: research
